RYR2 and catecholaminergic polymorphic ventricular tachycardia: This conclusion is in agreement with clinical facts showing that patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) due to RyR2 mutation only suffer arrhythmias after β-ARS.